Isolated Nuclions and Ribocapsids for Drug Targets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical and biotechnology industries lack effective biological targets for diagnosing and treating human diseases and disorders, particularly in relation to nuclion-mediated conditions such as certain cancers and viral infections.
Innovation Solution
Development of isolated nuclions comprising a core nucleic acid and ribocapsids, which can be manufactured and stabilized for use in pharmaceutical research and development, targeting specific nuclion-mediated diseases by modulating protein synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional pharmaceutical targets are used, then existing treatment approaches can be applied, but effective biological targets for diagnosing and treating nuclion-mediated diseases are lacking
Solution Approach 1:
The patent segments the protein synthesis machinery into distinct functional components: ribosomes, tRNAs, and mRNA. By isolating and characterizing specific nuclion structures (such as tRNA ribocapsids bound to mRNA), the invention creates discrete, identifiable biological targets that can be selectively addressed by pharmaceutical agents, resolving the lack of specific targets for nuclion-mediated diseases.
Solution Approach 2:
The patent identifies nuclions as intermediary structures that mediate between genetic information (mRNA) and protein synthesis execution (tRNAs and ribosomes). These intermediaries serve as accessible biological targets that can be targeted by diagnostic and therapeutic agents, providing a bridge between fundamental molecular processes and treatable disease states.
2Adaptability or versatility
If nuclions are isolated and characterized for pharmaceutical use, then new biological targets can be provided, but the complexity of manufacturing and stabilizing isolated nuclions increases
Solution Approach 1:
The patent employs preliminary characterization and stabilization of nuclion structures through controlled isolation procedures. By pre-characterizing the structural and functional properties of isolated nuclions (such as confirming tRNA ribocapsid binding to mRNA), the invention establishes standardized reference materials that simplify subsequent pharmaceutical development and reduce the complexity of manufacturing and quality control.
3Stability of the object's composition
If ribocapsid subunits are bound to core nucleic acid and adjacent ribocapsid subunits, then stable nuclion structures are formed, but the structural complexity and binding requirements increase
Solution Approach 1:
The patent merges multiple functional elements into integrated nuclion structures: tRNA ribocapsid subunits are combined with mRNA core nucleic acid and adjacent ribocapsid subunits to form stable, functional complexes. This merging creates synergistic structures where the binding interfaces between components enhance overall structural stability while maintaining biological functionality, effectively managing structural complexity through functional integration.
Data Source
AI summary
The invention relates to an isolated nuclion having (i) a core nucleic acid, and (ii) one or more ribocapsids each including a polymer of two or more ribocapsid subunits, wherein said ribocapsid subunits include nucleic acid. The invention also relates to a method for manufacturing an isolated nuclion.